Galectin Therapeutics Inc [GALT] stock is trading at $3.73, up 24.33%. An important factor to consider is whether the stock is rising or falling in short-term value. The GALT shares have gain 56.07% over the last week, with a monthly amount glided 79.33%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 29, March 2024, Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update. In a post published today on Yahoo Finance, Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2023.
From an analyst’s perspective:
Galectin Therapeutics Inc [NASDAQ: GALT] stock has seen the most recent analyst activity on August 13, 2020, when H.C. Wainwright reiterated its Buy rating and also boosted its price target to $12 from $9. Previously, B. Riley FBR started tracking the stock with Buy rating on February 13, 2019, and set its price target to $11. On December 07, 2017, H.C. Wainwright reiterated its Buy rating and revised its price target to $10 on the stock. H.C. Wainwright reiterated its Buy rating and increased its price target to $6 on November 28, 2017. ROTH Capital initiated its recommendation with a Buy. H.C. Wainwright upgraded its rating to Buy for this stock on March 30, 2017, but kept the price target unchanged to $3.50. In a note dated October 03, 2016, FBR & Co. downgraded an Mkt Perform rating on this stock and revised its target price from $12 to $2.
Galectin Therapeutics Inc [GALT] stock has fluctuated between $1.28 and $3.00 over the past year. Galectin Therapeutics Inc [NASDAQ: GALT] shares were valued at $3.73 at the most recent close of the market.
Analyzing the GALT fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -1.48, Equity is 0.82 and Total Capital is -3.04. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -1.19.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.23 points at the first support level, and at 2.72 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.99, and for the 2nd resistance point, it is at 4.24.
Galectin Therapeutics Inc [GALT] reported earnings per share of -$0.16 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.16/share, meaning a difference of $0 and a surprise factor of 0.00%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.24 per share as compared to estimates of -$0.16 per share, a difference of -$0.08 representing a surprise of -50.00%.
Ratios To Look Out For
For context, Galectin Therapeutics Inc’s Current Ratio is 1.77. On the other hand, the Quick Ratio is 1.77, and the Cash Ratio is 1.64.
Transactions by insiders
Recent insider trading involved ELDRED KARY, Director, that happened on Jan 16 ’24 when 500.0 shares were purchased. Director, ELDRED KARY completed a deal on Jul 19 ’23 to buy 1598.0 shares.
